<DOC>
	<DOCNO>NCT02263508</DOCNO>
	<brief_summary>Phase 1b Subjects treat talimogene laherparepvec injectable tumor disappear , disease progression per modify Immune-Related Response Criteria ( irRC ) , intolerance study treatment , maximum 24 month study treatment . Subjects treat MK-3475 ( pembrolizumab ) complete response ( CR ) disease progression per irRC , intolerance study treatment , maximum 24 month study treatment . In Phase 3 , Subjects treat talimogene laherparepvec plus pembrolizumab ( arm 1 ) placebo plus pembrolizumab ( arm 2 ) 24 month date first dose pembrolizumab end treatment due disappearance injectable lesion , complete response , disease progression per irRC-RECIST intolerance study treatment .</brief_summary>
	<brief_title>Pembrolizumab With Without Talimogene Laherparepvec Talimogene Laherparepvec Placebo Unresected Melanoma ( KEYNOTE-034 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Key Age â‰¥ 18 year histologically confirm diagnosis melanoma stage IIIB IVM1c surgery recommend . Subjects must measurable disease candidate intralesional therapy administration cutaneous , subcutaneous , nodal lesion . ECOG performance status 0 1 . Adequate hematologic , hepatic , renal , coagulation function . Subjects BRAFV600 wildtype tumor must receive prior systemic anticancer treatment consist chemotherapy , immunotherapy , target therapy give nonadjuvant set unresectable stage IIIB IVM1c melanoma . Subjects BRaf V600 ( BRAFV600 ) mutate tumor receive prior BRAF inhibitor therapy either alone combination MEK inhibitor prior systemic therapy eligible . Subjects receive prior adjuvant therapy melanoma exclude ( include , limited , interferon , ipilimumab , limb infusion/perfusion , use investigational agent adjuvant set ) exception prior adjuvant therapy inhibitor PD1 PDL1 allow . However , subject receive adjuvant therapy , subject must complete therapy least 28 day prior enrollment . Subjects must tumor sample adequate PDL1 assessment prior randomization . Key Subjects must clinically active cerebral metastasis . Subjects must primary uveal mucosal melanoma , history evidence melanoma associate immunodeficiency state history malignancy within past 3 year . Subjects may previously treat talimogene laherparepvec , oncolytic virus , pembrolizumab , inhibitor PD1 , PDL1 , PDL2 . Subjects must history evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease , document history autoimmune disease syndrome require systemic treatment past 2 year ( ie , use disease modify agent , steroid immunosuppressive agent ) except vitiligo resolve childhood asthma/atopy , evidence clinically significant immunosuppression . Subjects must active herpetic skin lesion prior complication herpetic infection must require intermittent chronic treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Talimogene Laherparepvec</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>KEYNOTE-034</keyword>
	<keyword>MASTERKEY-265</keyword>
</DOC>